Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832

Watchlist Manager
Shenzhen New Industries Biomedical Engineering Co Ltd Logo
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Watchlist
Price: 61.88 CNY -2.35% Market Closed
Market Cap: 48.6B CNY
Have any thoughts about
Shenzhen New Industries Biomedical Engineering Co Ltd?
Write Note

Shenzhen New Industries Biomedical Engineering Co Ltd
PP&E Gross

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen New Industries Biomedical Engineering Co Ltd
PP&E Gross Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Gross CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
PP&E Gross
ÂĄ1.4B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
PP&E Gross
ÂĄ7.3B
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
PP&E Gross
ÂĄ1.4B
CAGR 3-Years
70%
CAGR 5-Years
59%
CAGR 10-Years
N/A
Autobio Diagnostics Co Ltd
SSE:603658
PP&E Gross
ÂĄ4.1B
CAGR 3-Years
16%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Winner Medical Co Ltd
SZSE:300888
PP&E Gross
ÂĄ4.2B
CAGR 3-Years
41%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Intco Medical Technology Co Ltd
SZSE:300677
PP&E Gross
ÂĄ9.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen New Industries Biomedical Engineering Co Ltd
Glance View

Market Cap
48.6B CNY
Industry
Health Care

Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIB) stands at the forefront of innovation in the biomedical sector, specializing in the development and manufacturing of cutting-edge medical devices and diagnostic solutions. Founded in a thriving economic hub, Shenzhen, the company harnesses state-of-the-art technology and research expertise to deliver products that enhance healthcare outcomes. With a robust portfolio that spans various therapeutic areas, including critical care, cardiology, and infectious diseases, SNIB is not only committed to advancing healthcare but also to addressing pressing global health challenges. Their dedication to research and development, coupled with strategic partnerships with leading research institutions, positions them as a significant player in the rapidly expanding biomedical market. For investors, SNIB represents a compelling opportunity driven by a combination of strong growth potential and strategic ambition. The company has consistently demonstrated impressive revenue growth, complemented by a commitment to innovation, which has resulted in a growing pipeline of products that meet both current and emerging healthcare needs. With the rising demand for advanced medical solutions globally, SNIB is poised to leverage its technological strengths and market position to capture an increasing share of this burgeoning industry. Additionally, the company's proactive approach to regulatory compliance and quality assurance underscores its commitment to delivering safe and effective products, further enhancing investor confidence in its long-term viability and success.

Intrinsic Value
86.51 CNY
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Shenzhen New Industries Biomedical Engineering Co Ltd's PP&E Gross?
PP&E Gross
1.4B CNY

Based on the financial report for Dec 31, 2023, Shenzhen New Industries Biomedical Engineering Co Ltd's PP&E Gross amounts to 1.4B CNY.

What is Shenzhen New Industries Biomedical Engineering Co Ltd's PP&E Gross growth rate?
PP&E Gross CAGR 5Y
15%

Over the last year, the PP&E Gross growth was 6%. The average annual PP&E Gross growth rates for Shenzhen New Industries Biomedical Engineering Co Ltd have been 19% over the past three years , 15% over the past five years .

Back to Top